Você procurou por: ispitivanog (Croata - Inglês)

kvantifikacija ispitivanog lijeka
ftc/tdf groupa

faza ukrižene zamjene ispitivanog lijeka
crossover phase

prekid primanja ispitivanog lijeka zbog nuspojavaili smrtid
discontinued study drug due to ae or deathd

prekid primanja ispitivanog lijeka zbog nuspojava ili smrtic
discontinued study drug due to ae or deathc

tijekom ispitivanog razdoblja 9203 trudnice su rodile 9286 novorođenčadi .
durimg the observed period 9203 pregnant women gave birth to 9286 newborns .

prekid primanja ispitivanog lijeka zbog štetnih dogaĎaja ili smrtic
discontinued study drug due to ae or deathc

diferencijalnom pretražnom kalorimetrijom ustanovljena je nemješljivost ispitivanog homopolimera i terpolimera .
the immiscibility of homopolymer and terpolymer was estabilished by dsc method .

identifikaciju ispitivanog vozila, sastavnog dijela ili zasebne tehničke jedinice;
the identification of the vehicle, component or separate technical unit tested;

nastala dokazana ili vjerojatna invazivna gljivična infekcija tijekom uzimanja ispitivanog lijeka
developed proven or probable ifi while on study drug

prekid sudjelovanja u ispitivanju/primjene ispitivanog lijeka zbog drugih razloga§
discontinued study/study drug for other reasons§

na temelju prilagodbi ispitivanog liječenja za većinu je reakcija ocijenjeno da su posljedica infuzija docetaksela.
based on modifications made to the study treatment, most reactions were assessed as secondary to docetaxel infusions.

bolesnici su trebali biti podvrgnuti invazivnom liječenju nakon primanja ispitivanog lijeka tijekom 12 do 96 sati.
patients were to undergo an invasive strategy for further management after receiving study drug for 12 to 96 hours.

bolesnici su dobili upute da uzmu 1 dozu ispitivanog lijeka otprilike 30 minuta prije početka spolne aktivnosti.
patients were instructed to take 1 dose of study medication approximately 30 minutes prior to initiation of sexual activity.

4716 bolesnika podvrgnuto je perkutanoj koronarnoj angioplastici uz primjenu antikoagulantnog lijeka, sljedeći pravila za maskiranje ispitivanog lijeka.
4716 patients were treated with percutaneous coronary angioplasty with administration of anticoagulant following the rules for masking investigational medicinal product.

status s obzirom na preživljenje nakon 3 godine bio je utvrđen za sve bolesnike bez obzira na prestanak uzimanja ispitivanog lijeka.
survival status at 3 years was determined for all patients regardless of withdrawal from study medication.

primarni ishod ispitivanja bio je udio bolesnika s laksacijom bez primjene dodatnog laksativa unutar 4 sata nakon primjene dvostruko slijepe doze ispitivanog lijeka.
the primary endpoint was the proportion of patients with a rescue-free laxation within 4 hours of the double-blind dose of study medicinal product.

bolesnici u ne-mtx skupini ili nikad nisu uzimali metotreksat ili su ga prestali uzimati bar dva tjedna prije uzimanja ispitivanog lijeka.
patients who were in the non-mtx stratum were either naïve to or had been withdrawn from mtx at least two weeks prior to study drug administration.

u ispitivanju gist-a, primjena ispitivanog lijeka je prekinuta u 4 % bolesnika zbog nuspojava povezanih s primjenom imatiniba.
in gist the investigational medicinal product was discontinued for imatinib-related adverse reactions in 4 % of patients.

podaci o udjelu ispitanika koji su bili podvrgnuti kolektomiji u bilo kojem trenutku unutar 54 tjedna od prve infuzije ispitivanog lijeka prikupljeni su i objedinjeni iz ispitivanja act 1 i act 2 i njihovih nastavaka.
the proportion of subjects who underwent colectomy at any time within 54 weeks following the first infusion of study agent were collected and pooled from the act 1 and act 2 studies and their extensions.

alocf (last observation carried for povećanja doze inzulina, ako je potre bsvi randomizirani bolesnici koji su t ispitivanog lijeka u dvostruko slijepo csrednja vrijednost dobivena metodo peroralnih lijekova za snižavanje razi
alocf: last observation (prior to or o ball randomised subjects who took at l double-blind period cleast squares mean adjusted for basel